# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 17, "Arch Ophthalmol .", "", "<http://ctro/data#Publication_99335> <http://ctro/data#hasJournal> \"Arch Ophthalmol .\"."
1, PublicationYear, 18, 22, "1997", "", "<http://ctro/data#Publication_99335> <http://ctro/data#hasPublicationYear> \"1997\"."
16, Title, 52, 133, "A 1 - year study of brimonidine twice daily in glaucoma and ocular hypertension .", "", "<http://ctro/data#Publication_99335> <http://ctro/data#hasTitle> \"A 1 - year study of brimonidine twice daily in glaucoma and ocular hypertension .\"."
88, Duration, 54, 62, "1 - year", "", "<http://ctro/data#ClinicalTrial_99347> <http://ctro/data#hasCTduration> \"1 - year\"."
2, Brimonidine, 72, 83, "brimonidine", "", 
3, Frequency, 84, 95, "twice daily", "", 
4, Glaucoma, 99, 107, "glaucoma", "", "<http://ctro/data#Glaucoma_99356> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Glaucoma>. <http://ctro/data#ClinicalTrial_99347> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Glaucoma_99356>."
5, OcularHypertension, 112, 131, "ocular hypertension", "", "<http://ctro/data#ClinicalTrial_99347> <http://ctro/data#analysesHealthCondition> <http://ctro/data#OcularHypertension>."
24, Title, 134, 190, "A controlled , randomized , multicenter clinical trial .", "", 
93, CTDesign, 136, 146, "controlled", "", "<http://ctro/data#CTDesign_99353> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#CTDesign>. <http://ctro/data#ClinicalTrial_99347> <http://ctro/data#hasCTDesign> <http://ctro/data#CTDesign_99353>."
6, Randomized, 149, 159, "randomized", "", "<http://ctro/data#ClinicalTrial_99347> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
7, Multicenter, 162, 173, "multicenter", "", "<http://ctro/data#ClinicalTrial_99347> <http://ctro/data#hasCTDesign> <http://ctro/data#Multicenter>."
84, Brimonidine, 199, 210, "Brimonidine", "", 
9, Author, 225, 235, "Schuman JS", "", "<http://ctro/data#Publication_99335> <http://ctro/data#hasAuthor> \"Schuman JS\"."
10, Author, 244, 253, "Horwitz B", "", "<http://ctro/data#Publication_99335> <http://ctro/data#hasAuthor> \"Horwitz B\"."
11, Author, 256, 266, "Choplin NT", "", "<http://ctro/data#Publication_99335> <http://ctro/data#hasAuthor> \"Choplin NT\"."
12, Author, 269, 276, "David R", "", "<http://ctro/data#Publication_99335> <http://ctro/data#hasAuthor> \"David R\"."
13, Author, 279, 289, "Albracht D", "", "<http://ctro/data#Publication_99335> <http://ctro/data#hasAuthor> \"Albracht D\"."
14, Author, 292, 298, "Chen K", "", "<http://ctro/data#Publication_99335> <http://ctro/data#hasAuthor> \"Chen K\"."
15, USA, 409, 412, "USA", "", "<http://ctro/data#Population_99370> <http://ctro/data#hasCountry> <http://ctro/data#USA>."
17, Brimonidine, 510, 529, "Brimonidin tartrate", "", 
18, ObjectiveDescription, 572, 729, "This study investigates the safety and efficacy of 0 . 2 % brimonidine administered twice daily for 1 year in patients with glaucoma or ocular hypertension .", "", "<http://ctro/data#ClinicalTrial_99347> <http://ctro/data#hasObjectiveDescription> \"This study investigates the safety and efficacy of 0 . 2 % brimonidine administered twice daily for 1 year in patients with glaucoma or ocular hypertension .\"."
19, DoseValue, 623, 628, "0 . 2", "", 
25, Percentage, 629, 630, "%", "", 
26, Brimonidine, 631, 642, "brimonidine", "", 
20, Frequency, 656, 667, "twice daily", "", 
21, Duration, 672, 678, "1 year", "", 
54561, Precondition, 682, 727, "patients with glaucoma or ocular hypertension", "", "<http://ctro/data#Population_99370> <http://ctro/data#hasPrecondition> \"patients with glaucoma or ocular hypertension\"."
22, Glaucoma, 696, 704, "glaucoma", "", 
23, OcularHypertension, 708, 727, "ocular hypertension", "", 
27, Multicenter, 763, 774, "multicenter", "", 
28, DoubleBlind, 777, 792, "double - masked", "", "<http://ctro/data#ClinicalTrial_99347> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
29, Randomized, 795, 805, "randomized", "", 
30, Parallel, 808, 816, "parallel", "", "<http://ctro/data#ClinicalTrial_99347> <http://ctro/data#hasCTDesign> <http://ctro/data#Parallel>."
117, CTDesign, 827, 846, "active - controlled", "", "<http://ctro/data#CTDesign_99367> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#CTDesign>. <http://ctro/data#ClinicalTrial_99347> <http://ctro/data#hasCTDesign> <http://ctro/data#CTDesign_99367>."
32, DoseValue, 894, 899, "0 . 2", "", "<http://ctro/data#Medication_99444> <http://ctro/data#hasDoseValue> \"0 . 2\"."
120, Percentage, 900, 901, "%", "", "<http://ctro/data#Medication_99444> <http://ctro/data#hasDoseUnit> <http://ctro/data#Percentage>."
34, Brimonidine, 902, 913, "brimonidine", "", "<http://ctro/data#Medication_99444> <http://ctro/data#hasDrug> <http://ctro/data#Brimonidine>."
33, DoseValue, 917, 922, "0 . 5", "", "<http://ctro/data#Medication_99451> <http://ctro/data#hasDoseValue> \"0 . 5\"."
36, Percentage, 923, 924, "%", "", "<http://ctro/data#Medication_99451> <http://ctro/data#hasDoseUnit> <http://ctro/data#Percentage>."
35, Timolol, 925, 940, "timolol maleate", "", "<http://ctro/data#Medication_99451> <http://ctro/data#hasDrug> <http://ctro/data#Timolol>."
37, Frequency, 941, 952, "twice daily", "", "<http://ctro/data#Intervention_99431> <http://ctro/data#hasFrequency> \"twice daily\". <http://ctro/data#Intervention_99438> <http://ctro/data#hasFrequency> \"twice daily\"."
38, Duration, 957, 966, "12 months", "", 
126, TimePoint, 995, 1003, "baseline", "", 
127, TimePoint, 1006, 1012, "week 1", "", 
54563, TimePoint, 1019, 1035, "months 1 , 2 , 3", "", 
128, TimePoint, 1019, 1027, "months 1", "", 
130, TimePoint, 1019, 1031, "months 1 , 2", "", 
131, TimePoint, 1019, 1039, "months 1 , 2 , 3 , 6", "", 
132, TimePoint, 1019, 1043, "months 1 , 2 , 3 , 6 , 9", "", 
133, TimePoint, 1019, 1052, "months 1 , 2 , 3 , 6 , 9 , and 12", "", 
134, TimePoint, 1092, 1098, "week 2", "", 
39, NumberPatientsCT, 1114, 1117, "443", "", "<http://ctro/data#ClinicalTrial_99347> <http://ctro/data#hasNumberPatientsCT> \"443\"."
40, FinalNumPatientsCT, 1152, 1155, "374", "", "<http://ctro/data#ClinicalTrial_99347> <http://ctro/data#hasFinalNumberPatientsCT> \"374\"."
54564, FinalNumPatientsArm, 1181, 1184, "186", "", "<http://ctro/data#Arm_99413> <http://ctro/data#hasFinalNumPatientsArm> \"186\"."
43, Brimonidine, 1194, 1205, "brimonidine", "", 
42, FinalNumPatientsArm, 1210, 1213, "188", "", "<http://ctro/data#Arm_99422> <http://ctro/data#hasFinalNumPatientsArm> \"188\"."
44, Timolol, 1223, 1230, "timolol", "", 
45, Brimonidine, 1233, 1244, "Brimonidine", "", 
46, Mean, 1282, 1286, "mean", "", "<http://ctro/data#Mean_99380> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_99378> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_99380>."
142, Peak_IOP, 1287, 1291, "peak", "", "<http://ctro/data#Endpoint_99378> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Peak_IOP>."
47, IOP, 1305, 1325, "intraocular pressure", "", 
142, Peak_IOP, 1305, 1325, "intraocular pressure", "", "<http://ctro/data#Endpoint_99378> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Peak_IOP>."
48, IOP, 1328, 1331, "IOP", "", 
49, Reduction, 1337, 1342, "6 . 5", "", "<http://ctro/data#Outcome_99458> <http://ctro/data#hasChangeValue> \"6 . 5\"."
50, mmHg, 1343, 1348, "mm Hg", "", "<http://ctro/data#Endpoint_99378> <http://ctro/data#hasBaselineUnit> <http://ctro/data#mmHg>."
51, Timolol, 1351, 1358, "timolol", "", 
52, Mean, 1384, 1388, "mean", "", 
148, Peak_IOP, 1389, 1393, "peak", "", 
148, Peak_IOP, 1407, 1410, "IOP", "", 
53, IOP, 1407, 1410, "IOP", "", 
54, Reduction, 1414, 1419, "6 . 1", "", "<http://ctro/data#Outcome_99485> <http://ctro/data#hasChangeValue> \"6 . 1\"."
55, mmHg, 1420, 1425, "mm Hg", "", 
106391, ObservedResult, 1428, 1528, "Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 ( P < . 03 )", "", "<http://ctro/data#Outcome_99512> <http://ctro/data#hasObservedResult> \"Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 ( P < . 03 )\". <http://ctro/data#Outcome_99539> <http://ctro/data#hasObservedResult> \"Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 ( P < . 03 )\". <http://ctro/data#Outcome_99566> <http://ctro/data#hasObservedResult> \"Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 ( P < . 03 )\". <http://ctro/data#Outcome_99593> <http://ctro/data#hasObservedResult> \"Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 ( P < . 03 )\"."
56, Brimonidine, 1428, 1439, "Brimonidine", "", 
58, Mean, 1448, 1452, "mean", "", 
57, Peak_IOP, 1453, 1461, "peak IOP", "", 
59, Timolol, 1486, 1493, "timolol", "", 
60, TimePoint, 1497, 1503, "week 2", "", "<http://ctro/data#Outcome_99512> <http://ctro/data#hasTimePoint> \"week 2\". <http://ctro/data#Outcome_99539> <http://ctro/data#hasTimePoint> \"week 2\"."
61, TimePoint, 1508, 1515, "month 3", "", "<http://ctro/data#Outcome_99566> <http://ctro/data#hasTimePoint> \"month 3\". <http://ctro/data#Outcome_99593> <http://ctro/data#hasTimePoint> \"month 3\"."
62, PvalueDiff, 1518, 1526, "P < . 03", "", "<http://ctro/data#DiffBetweenGroups_99620> <http://ctro/data#hasPvalueDiff> \"P < . 03\". <http://ctro/data#DiffBetweenGroups_99629> <http://ctro/data#hasPvalueDiff> \"P < . 03\"."
158, Duration, 1638, 1646, "1 - year", "", 
66, ObservedResult, 1725, 1787, "Allergy was seen in 9 % of subjects treated with brimonidine .", "", "<http://ctro/data#Outcome_99665> <http://ctro/data#hasObservedResult> \"Allergy was seen in 9 % of subjects treated with brimonidine .\"."
105208, Ocular_Allergy, 1725, 1732, "Allergy", "", "<http://ctro/data#Endpoint_99383> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Ocular_Allergy>."
64, PercentageAffected, 1745, 1746, "9", "", "<http://ctro/data#Outcome_99665> <http://ctro/data#hasPercentageAffected> \"9\"."
65, Brimonidine, 1774, 1785, "brimonidine", "", 
54568, EndPointDescription, 1788, 1797, "Dry mouth", "", "<http://ctro/data#EndPointDescription_99389> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_99388> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_99389>."
71, ObservedResult, 1788, 1909, "Dry mouth was more common in the brimonidine - treated group than in the timolol - treated group ( 33 . 0 % vs 19 . 4 % )", "", "<http://ctro/data#Outcome_99692> <http://ctro/data#hasObservedResult> \"Dry mouth was more common in the brimonidine - treated group than in the timolol - treated group ( 33 . 0 % vs 19 . 4 % )\". <http://ctro/data#Outcome_99719> <http://ctro/data#hasObservedResult> \"Dry mouth was more common in the brimonidine - treated group than in the timolol - treated group ( 33 . 0 % vs 19 . 4 % )\"."
67, Brimonidine, 1821, 1832, "brimonidine", "", 
68, Timolol, 1861, 1868, "timolol", "", 
69, PercentageAffected, 1887, 1893, "33 . 0", "", "<http://ctro/data#Outcome_99692> <http://ctro/data#hasPercentageAffected> \"33 . 0\"."
70, PercentageAffected, 1899, 1905, "19 . 4", "", "<http://ctro/data#Outcome_99719> <http://ctro/data#hasPercentageAffected> \"19 . 4\"."
54576, EndPointDescription, 1916, 1950, "complaints of burning and stinging", "", "<http://ctro/data#EndPointDescription_99394> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_99393> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_99394>."
76, ObservedResult, 1916, 2067, "complaints of burning and stinging were more common in the timolol - treated group ( 41 . 9 % ) than in the brimonidine - treated patients ( 28 . 1 % )", "", "<http://ctro/data#Outcome_99746> <http://ctro/data#hasObservedResult> \"complaints of burning and stinging were more common in the timolol - treated group ( 41 . 9 % ) than in the brimonidine - treated patients ( 28 . 1 % )\". <http://ctro/data#Outcome_99773> <http://ctro/data#hasObservedResult> \"complaints of burning and stinging were more common in the timolol - treated group ( 41 . 9 % ) than in the brimonidine - treated patients ( 28 . 1 % )\"."
54569, EndPointDescription, 1930, 1937, "burning", "", 
54573, Stinging, 1942, 1950, "stinging", "", 
73, Timolol, 1975, 1982, "timolol", "", 
72, PercentageAffected, 2001, 2007, "41 . 9", "", 
75, Brimonidine, 2024, 2035, "brimonidine", "", 
74, PercentageAffected, 2057, 2063, "28 . 1", "", 
172, Headache, 2070, 2078, "Headache", "", "<http://ctro/data#Endpoint_99398> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Headache>."
77, ObservedResult, 2070, 2136, "Headache , fatigue , and drowsiness were similar in the 2 groups .", "", "<http://ctro/data#Outcome_99800> <http://ctro/data#hasObservedResult> \"Headache , fatigue , and drowsiness were similar in the 2 groups .\". <http://ctro/data#Outcome_99827> <http://ctro/data#hasObservedResult> \"Headache , fatigue , and drowsiness were similar in the 2 groups .\". <http://ctro/data#Outcome_99854> <http://ctro/data#hasObservedResult> \"Headache , fatigue , and drowsiness were similar in the 2 groups .\"."
54577, EndPointDescription, 2081, 2088, "fatigue", "", "<http://ctro/data#EndPointDescription_99404> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_99403> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_99404>."
54578, EndPointDescription, 2095, 2105, "drowsiness", "", "<http://ctro/data#EndPointDescription_99409> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_99408> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_99409>."
78, ObservedResult, 2137, 2194, "In general , the tolerance to medication was acceptable .", "", "<http://ctro/data#Outcome_99458> <http://ctro/data#hasObservedResult> \"In general , the tolerance to medication was acceptable .\". <http://ctro/data#Outcome_99485> <http://ctro/data#hasObservedResult> \"In general , the tolerance to medication was acceptable .\"."
79, Brimonidine, 2209, 2220, "Brimonidine", "", 
81, ConclusionComment, 2209, 2281, "Brimonidine is safe and effective in lowering IOP in glaucomatous eyes .", "", "<http://ctro/data#ClinicalTrial_99347> <http://ctro/data#hasConclusionComment> \"Brimonidine is safe and effective in lowering IOP in glaucomatous eyes .\"."
80, IOP, 2255, 2258, "IOP", "", 
178, Glaucoma, 2262, 2274, "glaucomatous", "", 
180, Brimonidine, 2282, 2293, "Brimonidine", "", 
82, ConclusionComment, 2282, 2416, "Brimonidine provides a sustained long - term ocular hypotensive effect , is well tolerated , and has a low rate of allergic response .", "", "<http://ctro/data#ClinicalTrial_99347> <http://ctro/data#hasConclusionComment> \"Brimonidine provides a sustained long - term ocular hypotensive effect , is well tolerated , and has a low rate of allergic response .\"."
83, PMID, 2475, 2482, "9230823", "", "<http://ctro/data#Publication_99335> <http://ctro/data#hasPMID> \"9230823\"."
